ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia ... 7thSpace Interactive (press release) In contrast with various pre-clinical studies, recent clinical trials suggest that high dose erythropoietin (EPO) treatment following kidney transplantation does not improve short-term outcome and that it even increases the risk of thrombotic events ... |
